# Moderna Inc.

Type: Company (MRNA)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/moderna-inc
Canonical HTML page: https://getbiobrief.com/entity/moderna-inc

## Timeline

- **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
- **2026-06-26**: Chip Tumble and Moderna Rally — PHLX chip index dropped 5.3% on AI profitability concerns. Apple rebounded 3.1%. Moderna hosted an investor event, sending its stock up nearly 13%. S&P 500 closed marginally lower.
- **2026-06-25**: Inflation Data Released and Apple Price Hike — May US inflation data showed a rise above 4%, fueled by energy costs from the Iran war. Apple raised prices on iPads and MacBooks, citing memory chip costs, leading to a sell-off in its shares.
- **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
- **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
- **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
- **2025-12-01**: Grants Rescinded — The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
- **2025-08-15**: Workaround Supported — FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns.
- **2024-01-01**: Collaboration Begins — Moderna starts working with the FDA on the design for its mRNA flu vaccine trials.
- **2022**: Post-Pandemic Decline — Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
- **2020**: COVID Vaccine Success — Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

## Recent coverage (3 stories)

### After 109% Rally, Moderna’s Pipeline Progress and 10% Revenue Goal
2026-07-21 00:07:40 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Full story: https://getbiobrief.com/story/moderna-bio-pipeline-revival-109

### Moderna Showcases Pipeline, Stock Surges 13%: Biotech's Big Day
2026-06-28 00:00:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moderna's investor event sent its shares soaring nearly 13%, marking a pivotal day for the biotech industry. The rally highlights how pipeline disclosures can dramatically move markets and reaffirm investor appetite for innovation.
Full story: https://getbiobrief.com/story/moderna-pipeline-event-13-percent

### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline
2026-03-16 00:16:43 · Sentiment: Negative · Impact: 8/10 · Sources: 2

Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.